Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Candida Antigen and Polidocanol for Common Warts
NCT06749665Not yet recruiting
- Sponsor
- Sohag University
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of 10XB101 in common warts (3 arms), sponsored by Sohag University. Primary endpoint: Size of Warts. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
10XB101
03
Conditions
common warts
Beyond the preview
Go deeper on NCT06749665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749665.